Ubiquitin-specific protease 22 as a prognostic biomarker in patients with various cancers: a meta-analysis

作者：Xia, Xiaochun; Guan, Zhifeng; Ge, Yangyang; Yang, Baixia; Huang, Canhong; Shen, Kang; Zhai, Xiaogang; Wu, Zhijun; Liu, Xiangyang^*; Cai, Jing^*

来源：International Journal of Clinical and Experimental Medicine, 2016, 9(12): 23247-23257.

• USP22
• cancer
• prognosis
• biomarker
• meta-analysis

Many studies have reported that elevated ubiquitin-specific protease 22 (USP22) expression was association with poor prognosis in various cancer patients. To evaluate the prognostic value of USP22 in cancers, a comprehensive meta-analysis of published studies was conducted. Eligible studies were identified via multiple search strategies through PubMed, Web of Science and Ovid. The literature search was stopped at 19 November 2015. This meta-analysis was performed by Stata statistical software version 12.0. Seventeen eligible articles with a total of 2465 patients were included in this meta-analysis. The results showed that increased USP22 expression was significantly association with poor overall survival (OS), poor disease-free survival (DFS) and poor disease-specific survival (DSS) or relapse-free survival (RFS). The pooled hazard ratio (HR) is 2.47 (95% CI: 1.97-3.11, P = 0.000), 2.66 (95% CI: 2.02-3.50, P = 0.000) and 1.56 (95% CI: 1.12-2.18, P = 0.009), respectively. In the subgroup analysis, elevated USP22 expression was significantly correlation with all variables including publication year, sample size, the type of cancer, the method of survival analysis and Newcastle-Ottawa Quality Assessment Scale (NOS) score. USP22 overexpression was significantly associated with some of clinicopathological parameters, such as histological grade and lymph node metastasis for OS and DFS, tumor stage for OS. However, USP22 overexpression was not significantly associated with gender and tumor stage for OS. Sensitivity analysis showed there was not individual study affecting the pooled HRs. No publication bias was observed in this meta-analysis. This meta-analysis indicates that USP22 may be a potential prognostic biomarker in cancer patients. Elevated USP22 is significantly associated with clinicopathological factors and poorer prognosis in a variety of cancers.

• 出版日期2016
• 单位南通市肿瘤医院; 南通大学